◀ Back to TP53

PSENEN — TP53

Text-mined interactions from Literome

Alves da Costa et al., J Neurosci 2006 (Alzheimer Disease) : We demonstrate that PS deficiency, catalytically inactive PS mutants, gamma-secretase inhibitors, and betaAPP or amyloid precursor protein-like protein 2 ( APLP2 ) depletion all reduce the expression and activity of p53 and lower the transactivation of its promoter and mRNA expression
Checler et al., Curr Alzheimer Res 2007 : Thus, we established that PS deficiency, catalytically inactive PS mutants, gamma-secretase inhibitors and betaAPP or APLP2 depletion reduced the expression and activity of p53 , and lowered the transactivation of its promoter and mRNA levels